Evidence map›Paper›PMID 32462735›Full record

ArticleThe Journal of pathology2020

Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas.

Paal W Wallace, Catleen Conrad, Sascha Brückmann, Ying Pang, Eduardo Caleiras, Masanori Murakami, Esther Korpershoek, Zhengping Zhuang, Elena Rapizzi, Matthias Kroiss and 16 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of pathology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.

  1. Guideline
  2. Immunohistochemistry and Mutation Analysis ofInternational journal of molecular sciences · 2020
    Trial
  3. Article
  4. Review
  5. A novel germline (c.314T>A)Frontiers in endocrinology · 2025
    Review
  6. Artificial Intelligence in Metabolomics: A Current Review.Trends in analytical chemistry : TRAC · 2024
    Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Precision Medicine in Phaeochromocytoma and Paraganglioma.Journal of personalized medicine · 2021
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 16 institutions in 8 countries.

Paal W WallaceInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.ORCID 0000-0002-5439-096X
Catleen ConradInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Sascha BrückmannInstitute of Pathology, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Ying PangEunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.
Eduardo CaleirasHistopathology Core Unit, Spanish National Cancer Research Centre (CNIO), Calle de Melchor Fernández Almagro, Madrid, Spain.
Masanori MurakamiMedizinische Klinik and Poliklinik IV, Ludwig-Maximilians-Universität München, Munich, Germany.
Esther KorpershoekDepartment of Pathology, Erasmus MC-University Medical Center Rotterdam, Rotterdam, The Netherlands.
Zhengping ZhuangSurgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Elena RapizziDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Matthias KroissDepartment of Internal Medicine, Division of Endocrinology, University Hospital, University of Würzburg, Würzburg, Germany.
Volker GudziolKlinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Hals-Chirurgie, Plastische Operationen, Städtisches Klinikum Dresden, Akademisches Lehrkrankenhaus der Technischen Universität Dresden, Dresden, Germany.
Henri Jlm TimmersDepartment of Internal Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands.
Massimo MannelliDepartment of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Jens PietzschDepartment of Radiopharmaceutical and Chemical Biology, Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany.
Felix BeuschleinMedizinische Klinik and Poliklinik IV, Ludwig-Maximilians-Universität München, Munich, Germany.
Karel PacakEunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.
Mercedes RobledoHereditary Endocrine Cancer Group, CNIO, Madrid, Spain and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
Barbara KlinkInstitute for Clinical Genetics, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Mirko PeitzschInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Anthony J GillRoyal North Shore Hospital, Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Sydney, Australia.
Arthur S TischlerDepartment of Pathology and Laboratory Medicine, Tufts University School of Medicine, Boston, MA, USA.
Ronald R de KrijgerDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Thomas PapathomasInstitute of Metabolism and Systems Research, University of Birmingham, Edgbaston, Birmingham, UK.
Daniela AustInstitute of Pathology, Tumor and Normal Tissue Bank of the UCC/NCT Dresden, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Graeme EisenhoferInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Susan RichterInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.ORCID 0000-0002-3549-2477
University Hospital Carl Gustav Carus · DENational Institutes of Health · USLudwig-Maximilians-Universität München · DEUniversity of Florence · ITCentre for Biomedical Network Research on Rare Diseases · ESErasmus MC · NLHelmholtz-Zentrum Dresden-Rossendorf · DELaboratoire National de Santé · LURadboud University Nijmegen · NLSpanish National Cancer Research Centre · ESStädtisches Klinikum Dresden · DEThe Edgbaston Hospital · GBThe University of Sydney · AUTufts University · USUniversity Medical Center Utrecht · NLUniversity of Würzburg · DE

Funding

Diagnosis, Pathophysiology And Molecular Biology of Pheochromocytoma and ParagangliomaZIAHD008735 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI PACAK, KAREL · 2009 to 2024
$28.4M
Hypoxia signaling in cancer developmentZIABC011773 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ZHUANG, ZHENGPING · 2017 to 2025
$13.0M
Intramural NIH HHS Z99 HD999999Intramural NIH HHS ZIA HD008735
6 · The paper itself

Abstract

Phaeochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours with a hereditary background in over one-third of patients. Mutations in succinate dehydrogenase (SDH) genes increase the risk for PPGLs and several other tumours. Mutations in subunit B (SDHB) in particular are a risk factor for metastatic disease, further highlighting the importance of identifying SDHx mutations for patient management. Genetic variants of unknown significance, where implications for the patient and family members are unclear, are a problem for interpretation. For such cases, reliable methods for evaluating protein functionality are required. Immunohistochemistry for SDHB (SDHB-IHC) is the method of choice but does not assess functionality at the enzymatic level. Liquid chromatography-mass spectrometry-based measurements of metabolite precursors and products of enzymatic reactions provide an alternative method. Here, we compare SDHB-IHC with metabolite profiling in 189 tumours from 187 PPGL patients. Besides evaluating succinate:fumarate ratios (SFRs), machine learning algorithms were developed to establish predictive models for interpreting metabolite data. Metabolite profiling showed higher diagnostic specificity compared to SDHB-IHC (99.2% versus 92.5%, p = 0.021), whereas sensitivity was comparable. Application of machine learning algorithms to metabolite profiles improved predictive ability over that of the SFR, in particular for hard-to-interpret cases of head and neck paragangliomas (AUC 0.9821 versus 0.9613, p = 0.044). Importantly, the combination of metabolite profiling with SDHB-IHC has complementary utility, as SDHB-IHC correctly classified all but one of the false negatives from metabolite profiling strategies, while metabolite profiling correctly classified all but one of the false negatives/positives from SDHB-IHC. From 186 tumours with confirmed status of SDHx variant pathogenicity, the combination of the two methods resulted in 185 correct predictions, highlighting the benefits of both strategies for patient management. © 2020 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Indexed as

Machine LearningMetabolomicsAdrenal Gland NeoplasmsCohort StudiesHead and Neck NeoplasmsHumansImmunohistochemistryMutationParagangliomaPheochromocytomaSuccinate DehydrogenaseSDHD protein, humanSuccinate DehydrogenasediagnosticsKrebs cycle metabolitesLC-MS/MSlinear discriminant analysismass spectrometrymetabolite profilingmulti-observerprediction modelssuccinate to fumarate ratiovariants of unknown significance

Identifiers

PMID32462735
PMCPMC7548960
OpenAlexW3032305800

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.